Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer Inbar Nardi-Agmon, MD, Manal Abud-Hawa, MSc, Ori Liran, MSc, Naomi.

Slides:

Advertisements

Similar presentations

Oral Glucose Tolerance Test as a Breath Challenge Diagnostic Tool in Lung Cancer (1)* Alkoby Layah (3) Abud Hawa Manal (1) Bar Yair (4) Cancilla John(1)

Advertisements

Breath Analysis For Lung Cancer Early Detection Ori Liran a, Manal Abud-Hawa b, Maya Ilouze a,c, Naomi Gai-Mor a, Shlomi Dekel a, Alon Ben-Nun d, Amir.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC Kai Chen, MD, Fei Zhou, MD, Wenxiang Shen,

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma Nicolas Guibert,

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy Sotirios Lakis,

Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer Inbar Nardi-Agmon, MD, Manal Abud-Hawa, MSc, Ori Liran, MSc, Naomi.

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Detection of Lung Cancer and EGFR Mutation by Electronic Nose System

A Case of Heart Failure after Treatment with Anti–PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells’ Subpopulations in the Peripheral Blood of Patients with Non–Small Cell Lung Cancer

Meghan Campo, MD, David Gerber, MD, Justin F. Gainor, MD, Rebecca S

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.

Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm Hilâl Tekatli, MD, Saar van ’t Hof, MD, Esther.

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors Hsin-Yi Wang, MD Journal of Thoracic.

Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival Bhawna Sirohi, MBBS, DCH, Sue Ashley, BSc,

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer W Jeffrey Petty, MD, Sommer N.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist Kitty Huang, MSc, MDCM, David A. Palma,

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping Sai-Hong Ignatius Ou, MD, PhD,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer Charles M. Rudin, MD, PhD,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Exhaled Breath Analysis with a Colorimetric Sensor Array for the Identification and Characterization of Lung Cancer Peter J. Mazzone, MD, MPH, Xiao-Feng.

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Every breath you take: The value of the electronic nose (e-nose) technology in the early detection of lung cancer Gaetano Rocco, MD, FRCSEd The Journal.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Josine Quispel-Janssen, MD, Vincent van der Noort, PhD, Jeltje F

Chien-Wei Chen, MD, Chin-Wei Kuo, MD Journal of Thoracic Oncology

A Primer on Health Economic Evaluations in Thoracic Oncology

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC Francesco Gelsomino, MD, Valentina.

Daniel B. Costa, MD, PhD, Susan E. Jorge, PhD, Jason P

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

S-1 Treatment for Chemorefractory Thymic Carcinoma

Follow-Up of Small (4 mm or Less) Incidentally Detected Nodules by Computed Tomography in Oncology Patients: A Retrospective Review Reginald F. Munden,

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

P2.03b-002 Efficacy and Safety of WBRT Combined with Endostar in Patients with Advanced Non-Small Cell Lung Cancer Xiaorong Dong, Ruiguang Zhang, Xican.

Non-invasive Breath Analysis of Pulmonary Nodules

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction.

Mark I. Block, MD The Annals of Thoracic Surgery

Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive.

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Mark A. Socinski, MD Journal of Thoracic Oncology

Volatolomics in cancer

Robert Comis, MD, The Passing of a “Lung Man”

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Haval Balata, MBChB, MRCP, Kwun M. Fong, M. B. B. S

Presentation transcript:

Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer Inbar Nardi-Agmon, MD, Manal Abud-Hawa, MSc, Ori Liran, MSc, Naomi Gai-Mor, MSc, Maya Ilouze, PhD, Amir Onn, MD, Jair Bar, MD, PhD, Dekel Shlomi, MD, Hossam Haick, PhD, Nir Peled, MD, PhD Journal of Thoracic Oncology Volume 11, Issue 6, Pages 827-837 (June 2016) DOI: 10.1016/j.jtho.2016.02.017 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Graphic representation of breath sampling and analysis procedure. (A) Collection of the breath sample in a single-step process into a chemically inert Mylar bag; (B) transfer of the bag's contents to Tenax sorbent tube; (C) thermal desorption to release the volatile organic compounds from the sorbent tube; (D) gas chromatography/mass spectrometry (GC-MS) to detect and analyze the compounds; and (E) sensor array containing gold nanoparticles with different modifications and polycyclic aromatic hydrocarbons. Journal of Thoracic Oncology 2016 11, 827-837DOI: (10.1016/j.jtho.2016.02.017) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Hot-plot for the follow-up of lung cancer states. Patients are represented by the rows, and columns give successive breath samples for each patient. The scale represents the normalized resistance of the sensor, as described before, and units are given in ohms. Samples not identified by the sensor are marked by black blocks. The red tones in the color scale represent increased resistance of the sensor, indicating a worsening of the disease, whereas the green tones represent a decrease in resistance of the sensor and indicate a positive response to treatment. PD, progressive disease; PR, partial response; SD, stable disease. Journal of Thoracic Oncology 2016 11, 827-837DOI: (10.1016/j.jtho.2016.02.017) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Selected example of consecutive CT scans for patient 17 in the study (73 years old with SCLC), with the corresponding breath samples and NA-NOSE sensor's resistance (given in ohm). ∗Before initiation of treatment. CT, computerized tomography; SCLC, small cell lung cancer; NA-NOSE, chemical nanoarray; PD, progressive disease; PR, partial response. Journal of Thoracic Oncology 2016 11, 827-837DOI: (10.1016/j.jtho.2016.02.017) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions